Health Recovery Solutions Acquires Rimidi to Expand Chronic Care Management

Why It Matters

By uniting acute‑phase RPM with outpatient chronic‑care analytics, HRS can offer health systems a seamless, data‑driven pathway that reduces costs and improves outcomes for high‑risk patients. The acquisition accelerates HRS’s entry into the fast‑growing CGM market and strengthens its competitive moat.

Key Takeaways

• HRS adds ambulatory chronic care to its RPM platform
• Rimidi’s CGM integration feeds data directly into EHRs
• Dr. Lucienne Ide becomes HRS’s chief medical officer
• Expected cost reductions via improved diabetes management
• Acquisition expands HRS into end‑to‑end longitudinal care

Pulse Analysis

Remote patient monitoring has matured from a niche telehealth tool into a core component of value‑based care, especially for post‑acute and hospital‑at‑home programs. HRS, with over a million patients monitored, has built a scalable infrastructure that handles high‑acuity alerts, device logistics, and payer contracts. Yet the market’s next frontier lies in linking that acute oversight with continuous, outpatient disease management—a gap that Rimidi’s platform is designed to fill. By integrating Rimidi’s software, HRS can extend its data capture beyond discharge, creating a unified patient journey that spans recovery to everyday health maintenance.

Rimidi’s strength resides in its deep integration with leading continuous glucose monitors such as Dexcom, FreeStyle Libre, and Eversense. Unlike generic data aggregators, Rimidi translates raw glucose streams into actionable insights embedded directly within electronic health record (EHR) workflows, enabling clinicians to intervene in real time. This capability addresses a critical bottleneck: the sheer volume of CGM data that often overwhelms providers. With HRS’s enterprise‑grade deployment model, health systems can now standardize diabetes monitoring across large populations, driving measurable reductions in A1c levels and hospital readmissions, as demonstrated by early partner results.

Strategically, the acquisition signals a broader industry shift toward end‑to‑end virtual care ecosystems. Insurers are expanding coverage for CGM devices, and providers are under pressure to demonstrate cost savings while improving chronic‑disease outcomes. HRS’s expanded portfolio positions it to capture a larger share of the $10 billion CGM market and to negotiate more favorable contracts with health systems seeking integrated solutions. The addition of Dr. Lucienne Ide as chief medical officer further reinforces a clinical‑first approach, likely accelerating product validation and regulatory pathways. Overall, the deal enhances HRS’s competitive moat, aligns with payer incentives, and sets a precedent for future RPM‑centric mergers aimed at holistic, longitudinal patient care.

Deal Summary

Health Recovery Solutions (HRS) announced the acquisition of Rimidi, an Atlanta‑based chronic disease management firm, to broaden its remote patient monitoring and longitudinal care capabilities. The deal, disclosed on March 5, 2026, integrates Rimidi’s CGM data platform into HRS’s enterprise remote care suite, with no financial terms disclosed.